ES2135480T3 - Nueva molecula de celula endotelial que media la union de linfocitos en el hombre. - Google Patents

Nueva molecula de celula endotelial que media la union de linfocitos en el hombre.

Info

Publication number
ES2135480T3
ES2135480T3 ES93913035T ES93913035T ES2135480T3 ES 2135480 T3 ES2135480 T3 ES 2135480T3 ES 93913035 T ES93913035 T ES 93913035T ES 93913035 T ES93913035 T ES 93913035T ES 2135480 T3 ES2135480 T3 ES 2135480T3
Authority
ES
Spain
Prior art keywords
man
vap
endothelial cell
molecula
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93913035T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotie Therapies Corp
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25404388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2135480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Application granted granted Critical
Publication of ES2135480T3 publication Critical patent/ES2135480T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE DESCRIBE UNA NUEVA MOLECULA DE CELULA DE ENDOTELIO VAP - 1, QUE TRANSMITE EL ENLACE LINFOCITO EN EL HOMBRE. EN ESTA INVENCION SE DESCRIBEN ANTICUERPOS MONOCLONALES ANTI - VAP - 1 Y EL ANTICUERPO MONOCLONAL 1B2, ASI COMO LA LINEA CELULAR HIBRIDA (DSMACC2041) QUE LA PRODUCE. LA INVENCION ADEMAS PROPORCIONA METODOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTO-INMUNES POR MEDIO DE LA ADMINISTRACION DE COMPUESTOS DE ENLACE VAP - 1, TALES COMO ANTICUERPOS ANTI - VAP - 1.
ES93913035T 1992-06-09 1993-06-09 Nueva molecula de celula endotelial que media la union de linfocitos en el hombre. Expired - Lifetime ES2135480T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89535492A 1992-06-09 1992-06-09

Publications (1)

Publication Number Publication Date
ES2135480T3 true ES2135480T3 (es) 1999-11-01

Family

ID=25404388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93913035T Expired - Lifetime ES2135480T3 (es) 1992-06-09 1993-06-09 Nueva molecula de celula endotelial que media la union de linfocitos en el hombre.

Country Status (14)

Country Link
EP (1) EP0656906B1 (es)
JP (2) JP3431922B2 (es)
KR (1) KR100268772B1 (es)
AT (1) ATE184315T1 (es)
AU (1) AU671837B2 (es)
CA (1) CA2137551C (es)
DE (1) DE69326347T2 (es)
DK (1) DK0656906T3 (es)
ES (1) ES2135480T3 (es)
FI (1) FI121176B (es)
GR (1) GR3031255T3 (es)
HU (1) HU217175B (es)
NZ (2) NZ299958A (es)
WO (1) WO1993025582A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289903A1 (en) * 1997-05-23 1998-11-26 Oy Biotie Therapies, Ltd. Vascular adhesion protein-1 having amine oxidase activity
FI20020807A0 (fi) * 2002-04-29 2002-04-29 Biotie Therapies Oyj Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
FI20061156A0 (fi) 2006-12-27 2006-12-27 Elina Kivi Uusia peptidejä
FI20075278A0 (fi) 2007-04-20 2007-04-20 Biotie Therapies Corp Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69406664T2 (de) * 1993-06-18 1998-06-04 Biotie Therapies Oy Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6

Also Published As

Publication number Publication date
JP3500384B2 (ja) 2004-02-23
CA2137551C (en) 2002-03-26
WO1993025582A1 (en) 1993-12-23
NZ253151A (en) 1997-03-24
HU9403516D0 (en) 1995-02-28
KR950701938A (ko) 1995-05-17
AU671837B2 (en) 1996-09-12
EP0656906B1 (en) 1999-09-08
ATE184315T1 (de) 1999-09-15
HUT75824A (en) 1997-05-28
GR3031255T3 (en) 1999-12-31
AU4328193A (en) 1994-01-04
EP0656906A1 (en) 1995-06-14
FI121176B (fi) 2010-08-13
CA2137551A1 (en) 1993-12-23
DE69326347D1 (de) 1999-10-14
KR100268772B1 (ko) 2000-10-16
JP2003180346A (ja) 2003-07-02
DK0656906T3 (da) 1999-12-20
HU217175B (hu) 1999-12-28
NZ299958A (en) 2000-07-28
JPH07507557A (ja) 1995-08-24
FI20095269A (fi) 2009-03-16
DE69326347T2 (de) 2000-02-24
JP3431922B2 (ja) 2003-07-28

Similar Documents

Publication Publication Date Title
DE60231651D1 (de) Proteinreinigungsverfahren
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
DE69429095D1 (de) Humanisierte antikoerper
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DE69233791D1 (de) Verfahren zur Manipulation der Zelldifferenzierung
Baughn et al. Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis.
FI893575A (fi) Antigenstrukturer av çmajor histocompatibility complexç antigener av klass i med specifika baerarmolekyler, framstaellning och anvaendning daerav.
ATE142789T1 (de) Träger zur bindung von antiphospholipid- antikörpern, diese antikörper verwendender immunotest und kit dafür
ES2154728T3 (es) Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2.
ATE248190T1 (de) Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
DK407987D0 (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
DE3884316D1 (de) Synthetische Peptide, gegen diese gerichtete Antikörper und deren Verwendung.
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
FR2599513B1 (fr) Anticorps monoclonaux inhibant la liaison de ige soluble aux lymphocytes humains, hybridomes monoclonaux produisant de tels anticorps, leur utilisation
AR023204A1 (es) Anticuerpos contra la proteina placentaria 13.
DE69227918D1 (de) VERWENDUNG EINES CDw52-SPEZIFISCHEN ANTIKÖRPERS ZUR BEHANDLUNG VON DURCH T-ZELLEN VERMITTELTEN GELENKENTZÜNDUNGEN
ATE281471T1 (de) Antikörper-testbesteck zur bestimmung von amylin

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 656906

Country of ref document: ES